What is the most common cause of obstruction of plastic biliary stents in patients who have had a cholecystectomy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Bacterial Biofilm Formation is the Most Common Cause

The most common cause of plastic biliary stent obstruction in post-cholecystectomy patients is bacterial biofilm formation with subsequent sludge accumulation in the stent lumen 1, 2.

Mechanism of Obstruction

Plastic biliary stents occlude through a well-established process:

  • Bacterial colonization occurs rapidly after stent placement, with polymicrobial biofilm developing on the stent surface
  • The biofilm composition includes both Gram-positive and Gram-negative organisms (Enterococcus faecium, E. coli, Enterobacter cloacae, Klebsiella oxytoca, Proteus species, among others) 1
  • The distal portion of the stent (closest to the duodenum) shows the highest bacterial burden, with colony counts reaching 10^14 CFU compared to only 10^8-10^9 in proximal segments 1
  • This bacterial overgrowth leads to biliary sludge accumulation and progressive luminal narrowing

Critical Timing Considerations

Plastic stents have an average patency of only 63 days (approximately 2 months), with standard recommendations for removal or exchange within 3 months 3, 4, 5. After this period, the risk of occlusion and complications increases substantially.

High-Risk Factors for Earlier Occlusion

Certain patients require more aggressive surveillance and earlier stent exchange 4:

  • History of cholangitis during index ERCP (HR = 1.83)
  • Underlying malignancy as indication for stenting (HR = 1.34)
  • Multiple stents placed (HR = 1.73)

Clinical Pitfalls

A critical caveat: the gallbladder status itself does not fundamentally change the mechanism of plastic stent occlusion—bacterial biofilm remains the primary culprit regardless of cholecystectomy status. The question's premise may be misleading, as biofilm formation is the universal mechanism of plastic stent obstruction 2.

Common Complications of Retained Stents

When stents remain beyond recommended intervals 3, 5:

  • Recurrent cholangitis (up to 50% with prolonged stenting) 6
  • Stentolith formation (stone formation around the stent) 7
  • Biliary sepsis
  • Rarely, migration with perforation

Prevention Strategy

Implement a systematic tracking system to ensure timely stent removal at 2-3 months 3:

  • Use stent cards or digital reminders
  • Schedule elective exchange before emergency presentations occur
  • For high-risk patients (malignancy, prior cholangitis, multiple stents), consider exchange at 6-8 weeks rather than 3 months

The key distinction: while stones may accumulate around a forgotten stent creating a "stent-stone complex" 7, the primary mechanism of obstruction is always bacterial biofilm with sludge, not stone formation per se.

Related Questions

Can cholangitis occur after gallbladder removal?
How should I manage a patient who develops elevated liver function tests, jaundice, anorexia, and weakness after ERCP with biliary stent placement?
How soon after endoscopic retrograde cholangiopancreatography (ERCP) biliary stent placement should outpatient imaging be performed for plastic versus self‑expanding metal stents?
In a patient with cholecystitis and a stent (endoscopic stent) placement, should the stent be removed first or should a cholecystectomy be performed first?
Why is ERCP (Endoscopic Retrograde Cholangiopancreatography) performed first to remove the common bile duct (CBD) stone in a patient with acute cholecystitis and concurrent choledocholithiasis before proceeding with cholecystectomy?
What are the screening guidelines for low‑dose chest CT in adults aged 50–80 with at least a 20 pack‑year smoking history who are current smokers or have quit within the past 15 years?
What is the optimal glucagon-like peptide-1 receptor agonist (GLP‑1RA) regimen for a patient with type 2 diabetes, stage 4 chronic kidney disease, and chronic pancreatitis?
What are the hemoglobin target range and erythropoiesis‑stimulating therapy guidelines for children with chronic kidney disease?
Can a pregnant patient with a history of vertebral artery dissection have a vaginal delivery?
Does consuming raw flour cause stomach irritation or gastrointestinal illness?
In a patient with type 2 diabetes who is already taking insulin glargine (Lantus) 32 units nightly, has an elevated A1c despite therapy, and is on a GLP‑1 receptor agonist, how should the basal insulin be titrated and should rapid‑acting (prandial) insulin be added?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.